MedTrace Logo

COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications

NCT04771611 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2023-08-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test whether Fisetin, a senolytic drug can assist in the reduction of complications in patients with COVID-19 infection.

Conditions

  • Covid19
  • Coronavirus Infection

Interventions

DRUG

Fisetin

\~20mg/kg /day oral for four days (days 0,1 and days 8,9)

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient . Oral for four days (days 0,1 and days 8,9)

Sponsors & Collaborators

  • James L. Kirkland, MD, PhD

    lead OTHER

Principal Investigators

  • Avni Y. Joshi, MD, MS · Mayo Clinic

  • James L Kirkland, MD, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-14
Primary Completion
2022-09-27
Completion
2022-09-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04771611 on ClinicalTrials.gov